---
title: "PALOMA-2"
slug: "paloma"
date: "2023-12-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer]]

# PALOMA-2

Palbociclib and Letrozole in Advanced Breast Cancer

- åœ¨ä¸€é …åç‚ºPALOMA-2çš„Phase 3çš„ç ”ç©¶ç™¼ç¾ï¼šé‡å°æœªæ¥å—éé€²éšæ²»ç™‚çš„ERé™½æ€§ã€HER2é™°æ€§çš„ä¹³è…ºç™Œæ‚£è€…ï¼Œä½¿ç”¨palbociclibåŠ letrozoleç›¸è¼ƒæ–¼åƒ…ä½¿ç”¨letrozoleï¼Œåœ¨ âœ– ç„¡ç–¾ç—…é€²å±•ç”Ÿå­˜æœŸæ–¹é¢ï¼Œåˆ†åˆ¥æ˜¯24.8å€‹æœˆå°ä¸Š14.5å€‹æœˆ
- æ­¤å¤–ï¼Œç›¸æ¯”æ–¼å°ç…§çµ„ï¼Œä½¿ç”¨palbociclibåŠ letrozoleçš„ä¸»è¦å‰¯ä½œç”¨æœ‰ï¼šä¸­æ€§çƒæ¸›å°‘ â†“ ç—‡ (66.4ï¼… vs 1.4ï¼…) ã€ç™½ç´°èƒæ¸›å°‘ â†“ ç—‡ (24.8ï¼… vs 0ï¼…) ã€è²§è¡€ (5.4ï¼… vs 1.8ï¼…) å’Œç–²å‹ (1.8ï¼… vs 0.5ï¼…) ã€‚

N Engl J Med 2016; 375:1925-1936

## Palbociclib plus Letrozole for Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

- **Design:** Phase 3, double-blind, randomized clinical trial
- **Number of patients:** 666 postmenopausal women
- **Patients characteristics:** Postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, who had not had prior treatment for advanced disease
- **Agent:** Palbociclib plus Letrozole vs. Placebo plus Letrozole
- **Treatment line:** Initial treatment for advanced disease
- **Trial Name/NCT Number:** PALOMA-2 ClinicalTrials.gov number, NCT01740427

### Comparison of Palbociclib plus Letrozole vs. Placebo plus Letrozole

| Endpoints | Palbociclib plus Letrozole | Placebo plus Letrozole                    |
| --------- | -------------------------- | ----------------------------------------- |
| PFS       | Median 24.8 months         | Median 14.5 months (95% CI, 12.9 to 17.1) |

- **Other findings:**
  - The most common grade 3 or 4 adverse events were neutropenia, leukopenia, anemia, and fatigue.
  - Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group.
  - Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group.

### Summary

Palbociclib plus Letrozole significantly improved progression-free survival in postmenopausal women with previously untreated ER-positive, HER2-negative advanced breast cancer compared to Letrozole alone. However, myelotoxic effects were higher with palbociclib-letrozole.

åœ¨ä¸€é …åç‚º{trial}çš„Phase{1,2,or 3}çš„ç ”ç©¶ç™¼ç¾ï¼šé‡å°{patient characteristics}çš„ç—…äººï¼Œä½¿ç”¨{agents}ç›¸è¼ƒæ–¼{control}ï¼Œåœ¨{primary outcome}ä¸Šåˆ†åˆ¥æ˜¯{survival months}å€‹æœˆå°ä¸Š{months}å€‹æœˆ
